71dc8f95-3c46-4b9a-a57a-dfa229447bb8_figure12

[There seems to be a lot of interest in “Morgellons” posts here and at my other blogs.  So, even though I did post this on FB etc, I believe this piece deserves its own blog post.  Thanks, Rose.]

#Morgellons #MorgellonsDisease #MD #BorrelialDermatitis

[MD news you can use — I’m still not convinced there’s a chemTrail – Morgellons connection. Let’s get these people the meds they need.]

Morgellons: a novel dermatological perspective as the multisystem infective disease borreliosis

http://f1000research.com/articles/2-118/v1

Management and prognosis

There has been considerable debate about MD treatments.

To date, an exhaustive list of home remedies can be found on the internet, but evidence supporting the efficacy of these treatments is lacking.

Segments of the profession have tried therapy with antihelminthics including ivermectin, mebendazole, praziquantel and albendazole, but this approach as sole therapy is by and large ineffective and false conclusions as to their efficacy can be drawn by the cycling nature of the dermopathy.

No published material is available supporting such use.

The lead author has found that adequate treatment of B. burgdorferi will suppress and control the disorder, more easily so in earlier disease (unpublished observations).

Such treatment requires simultaneous antibiotic polypharmacy.

Cell wall drugs are useful for the extracellular spirochete forms, tetracyclines or macrolides are useful for the intracellular forms, while imidazole compounds such as metronidazole and tinidazole are useful for the cystic forms of B. burgdorferi.

In conjunction with LD treatment, the myriad associated coinfections need to be addressed including Anaplasma, Babesia, Bartonella, Ehrlichia and Rickettsia.

With advancing knowledge of cell-wall deficient forms of the Lyme spirochete, the mechanisms associated with chronic protracted LD are being understood, albeit slowly 41,42.

This knowledge also helps us to understand why skin examination looking only for spirochetes can be unrewarding as given the right conditions both the intracellular and cystic forms can morph back to a spirochetal form.

A recent study highlighted the significant burden of protracted LD patient care on healthcare systems 43, and delayed diagnosis of MD and LD adds to that burden.

We do not know if skin co-infections can be excluded at this juncture, nor can we rule out the possibility of co-factors playing a crucial role in filament formation.

These are areas for ongoing research as is the exact mechanism of filament production.

To date the long-term prognosis for protracted LD illness that includes MD remains unsettled.

[….]

Research needs to be directed at identifying the fundamental flaw in filament production at the cellular level, which may involve RNA/DNA dysfunction, in the hope of addressing further treatment.

71dc8f95-3c46-4b9a-a57a-dfa229447bb8_figure1

Short Version:

#Morgellons #MorgellonsDisease #MD #BorrelialDermatitis

[MD news you can use — Let’s get these people the meds they need.]

http://tl.gd/n_1rv9e8s

71dc8f95-3c46-4b9a-a57a-dfa229447bb8_figure3

Scribd doc I put together — Discusses treatment regimen, also contact information:

http://www.scribd.com/doc/171027274/For-Morgellons-Disease-Patients-Dr-Stricker-in-San-Francisco-Prescribed

71dc8f95-3c46-4b9a-a57a-dfa229447bb8_figure4

[Above: Images are from the article cited above.]

About “sisterrosetta”

Unrelated, but @ approx 21:15 please see example of Morgellons fibrosis? organism? (IDK what it is) I removed from lower right jaw. Any MD patient will tell you this is par for the course.

Speaking of “fibrosis” — Soon I’ll be uploading a scribd doc which will include the following:

“rBCG-OspA strain” “B. burgdorferi, the etiological agent for Lyme disease” fibrosis patent engineer “foreign transgenic proteins” spray “simian models and human clinical trials”

The ability to generate robust cytotoxic T lymphocyte (CTL) and T helper cell responses in combination with antibody responses, all targeted to mucosal surfaces, suggest that rBCG has potential as an effective vaccine vector.

However, as a derivative of the pathogenic M. bovis strain, rBCG contains genes that limit the effective immune response against a transgenic protein.

First generation recombinant BCG vaccines have been created and tested in simian models and human clinical trials with some success [9-12].

The robust BCG vector-specific responses suggest the potential of this vaccine, although responses of the same magnitude against a transgenic protein have not been realized.

There is good reason to believe that the limitations that exist in using rBCG as a vector vaccine reflect the biology of BCG, and that elimination of these limitations would substantially increase the potential of BCG as a vaccine vector.

There is need to engineer BCG so as to address these limitations and harness BCG as a vaccine vector.

[….]

Delivery Methods

Once formulated, the rBCG vector compositions of the invention can be delivered to a mammalian subject (e.g., a human or other mammal described herein) in vivo using a variety of known routes and techniques.

For example, a composition can be provided as an injectable solution, suspension or emulsion and administered via parenteral, subcutaneous, epidermal, intradermal, intramuscular, intraarterial, intraperitoneal, and intravenous injection and by intra-pulmonary inoculation using a conventional needle and syringe, a liquid jet injection system, or other methods known in the art.

Compositions can also be administered topically to skin or mucosal tissue, such as

nasally,

inlratracheally,

intestinal,

rectally or vaginally, or provided as

a finely divided spray suitable for respiratory or

pulmonary administration (e.g., for intra-pulmonary inoculation).

Other modes of administration include oral administration, suppositories, and active or passive transdermal delivery techniques.

Particularly in relation to the present invention, compositions may be administered directly to the gastrointestinal tract.

Alternatively, the the rBCG vector compositions can be administered ex vivo, for example,

by delivery and reimplantation of transformed cells into a mammalian subject

(e.g., a human or other mammal described herein).

http://www.sumobrain.com/patents/wipo/Mycobacterial-vaccine-vectors-methods-using/WO2012138754A2.pdf

Probably I am “grasping at straws” — But since all of these are related: rBCG-OspA “lyme disease” fibrosis … Perhaps there is an OspA – Morgellons connection? I taught middle school science, but understanding the science of this is …

“I use [only] forty-eight percent of my brain.”

sumobrain_logo

+++

Advertisements